secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000939767-23-000035
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis files patent infringement suit against Cipla over generic CABOMETYX
----------------------------------------------------------------------------

- Filed complaint in Delaware district court against Cipla for ANDA seeking approval of generic cabozantinib tablets (20/40/60 mg).
- Five patents asserted: U.S. Patents Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 11,298,349, with latest expiry Feb. 10, 2032.
- Exelixis seeks injunction and order delaying any FDA approval until after patent expirations; Cipla did not challenge compound patent expiring Aug. 14, 2026.
- CABOMETYX is a key revenue driver for Exelixis; generic entry could impact sales if patents are invalidated or not infringed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000035/0000939767-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000035/exel-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer